Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialHaruhiro Saito, Makoto Maemondo, Ou Yamaguchi et al.|The Lancet Oncology|2019Cited by 636
Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene MutationsAkira Inoue, Toshihiro Nukiwa, Takuji Suzuki et al.|Journal of Clinical Oncology|2006Cited by 504
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 StudyYukio Hosomi, Satoshi Morita, Shunichi Sugawara et al.|Journal of Clinical Oncology|2019Cited by 483
Activation of Cdc42 by trans interactions of the cell adhesion molecules nectins through c-Src and Cdc42-GEF FRGTatsuro Fukuhara, Yoshimi Takai|The Journal of Cell Biology|2004Cited by 108